A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

NCT07660796 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1803-3
DRUG: HCP1803-4
DRUG: RLD2001-1
DRUG: RLD2001-2

Sponsor

Hanmi Pharmaceutical Company Limited